Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs Cytokinetics Inc (CYTK) Price & Performance

Autodesk IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Autodesk Inc vs Cytokinetics Inc — how do they compare? Autodesk Inc trades at $247.35 (market cap $53.12B), while Cytokinetics Inc trades at $76.48 (market cap $10.63B). The key difference: Autodesk Inc is far larger — about 5× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.

ADSKCYTK
Market Cap
$53.12B$10.63B
Sector
TechnologyTechnology
52-Week High
$326.79$87.26
52-Week Low
$187.72$34.31
Enterprise Value
$52.92B$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.

The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK